Anti-PD-1 Immunotherapy Combined With SBRT for Patients With Oligometastatic ESCC
Status:
Recruiting
Trial end date:
2025-07-01
Target enrollment:
Participant gender:
Summary
The goal of this phase II clinical trial is to explore the efficacy and safety of anti-PD1
combined with stereotactic body radiation therapy (SBRT) for patients with oligometastatic
esophageal squamous cell carcinoma. Participants will receive anti-PD1 and SBRT to the
metastatic lesions which are amenable to the delivery of SBRT after 4~6 cycles of systemic
chemotherapy and anti-PD-1.